

Title

Preclinical development of vancomycin polycationic peptide conjugate (V_N-R₆C) with high antimicrobial activity *in vitro* and *in vivo*

Authors

Eric Mühlberg^{1,2}, Sabrina Wohlfart², Tyra Christian², Tobias Hertlein³, Knut Ohlsen³, Stefan Zimmermann⁴, Walter Mier², Philipp Uhl^{1,2}

Affiliation:

¹ Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany

² Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany

³ Institute for Molecular Infection Biology, University of Würzburg, Würzburg, Germany

⁴ Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany

Keywords

Antibiotics, vancomycin, polycationic peptides, enterococci, multidrug-resistant bacteria

Abstract

Multidrug-resistant bacteria are considered as one of the most imminent threats to modern medicine worldwide. While there are numerous drugs available for standard therapy, there are only a few compounds capable of serving as a last resort treatment for severe infections. Especially, infections caused by the ESKAPE pathogens are associated with numerous types of resistances. Therefore, approaches to treat infections with multidrug-resistant bacteria must be implemented.

Here, a strategy of reactivating the established glycopeptide antibiotic vancomycin by structural modification with a hexa-arginine polycationic peptide was investigated. The conjugate synthesis provided yields of over 65% in each of the two reaction steps required. The lead conjugate V_N-R₆C showed high antimicrobial potential on over 50 clinical isolates of linezolid- and/or vancomycin-resistant enterococci (VRE, LVRE; Figure 1). The higher antimicrobial activity was also demonstrated by improved killing kinetics against selected strains. Radiolabeling with ¹²⁵I enabled the *in vivo* determination of the pharmacokinetics in SWISS mice by molecular imaging and biodistribution studies. In comparison to unmodified vancomycin, an altered biodistribution profile was observed. While vancomycin is rapidly excreted by the kidneys, the polycationic-conjugate shows a hepatobiliary excretion profile. *In vitro* biocompatibility studies on liver (Hep-G2 and primary human hepatocytes), kidney (HEK-293) and human red blood cells as well as a murine toxicity study showed no relevant toxicity. Further ADME screening, including serum, plasma and S9 liver microsome stability and metabolite profiling, CYP-inhibition and hERG-channel blocking emphasized drug-like properties. The *in vivo* efficacy of the conjugate was confirmed by VRE infection models in *G. mellonella*. Additionally, a systemic vancomycin-susceptible *S. aureus* murine infection model resulted in a significant reduction of CFU in the liver. The transfer to murine VRE infection models is still ongoing. In conclusion, these results highlight the drug-like properties of the lead conjugate V_N-R₆C. The combination of low toxicity and high *in vivo* efficacy of the hexa-arginine vancomycin conjugate makes it well suitable for further preclinical and potential clinical development as new antibiotic against multidrug-resistant bacteria.




Figure 1: Minimal inhibitory concentration (MIC) of vancomycin and the polycationic-peptide conjugate V_N-R₆C on over 50 VRE clinical isolates, including *vanA* and *vanB*-type resistant *E. faecalis* and *E. faecium*. The dotted lines indicate the concentration (4 mg/L) at which bacterial strains are considered to be resistant towards vancomycin.